IMMUNEONCO-B

🇭🇰Hong Kong, China

Country: 🇭🇰Hong Kong, China

Ownership: -

Established: 2015-06-18

Employees: 150

Market Cap: -

Website: http://cn.immuneonco.com

Introduction: Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. is a scientific research-oriented biotechnology company dedicated to developing innovative cancer immunotherapy. The company was incorporated in 2015 and is one of the few biotechnology companies in the world that can systematically utilize innate immunity and adaptive immune systems. By strictly adheri...

Clinical Trials

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Phase 3

Recruiting

Conditions: Chronic Myelomonocytic Leukemia

Interventions: Drug: IMM01
Drug: Azacitidine
Drug: Placebo

First Posted Date: 2024-10-18

Last Posted Date: 2024-10-22

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 170

Registration Number: NCT06647862

Locations: 🇨🇳
Zhujiang Hospital of Southern Medical University, Zhujiang, Guangdong, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangzhou, China
🇨🇳
The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

and more 19 locations

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Phase 3

Not yet recruiting

Conditions: Classic Hodgkin Lymphoma

Interventions: Biological: Tislelizumab
Drug: Bendamustine
Biological: IMM01
Drug: Gemcitabine

First Posted Date: 2024-06-18

Last Posted Date: 2024-06-24

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 202

Registration Number: NCT06465446

A Study Of IMM47 In Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Oncology

Interventions: Drug: IMM47

First Posted Date: 2023-08-14

Last Posted Date: 2023-10-04

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 48

Registration Number: NCT05985083

Locations: 🇦🇺
Scientia Clinical Research Ltd, NSW, Sydney, New South Wales, Australia
🇦🇺
Icon Cancer Centre South Brisbane, QLD, Brisbane, Queensland, Australia
🇦🇺
John Flynn Private Hospital, Gold Coast, Queensland, Australia

and more 1 locations

IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: IMM2510

First Posted Date: 2023-08-02

Last Posted Date: 2023-08-02

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 108

Registration Number: NCT05972460

Locations: 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

and more 1 locations

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Phase 1

Terminated

Conditions: Hematologic Malignancy

Interventions: Drug: IMM01

First Posted Date: 2023-05-16

Last Posted Date: 2023-05-16

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 73

Registration Number: NCT05860075

Locations: 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College,, Tianjin, Tianjin, China

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Phase 1

Recruiting

Conditions: Solid Tumor
Classic Hodgkin Lymphoma

Interventions: Drug: IMM01
Drug: Tislelizumab

First Posted Date: 2023-04-27

Last Posted Date: 2023-04-27

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 309

Registration Number: NCT05833984

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳
Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China
🇨🇳
The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China

and more 2 locations

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Phase 1

Recruiting

Conditions: CD20-positive B-cell Non-Hodgkin's Lymphoma

Interventions: Drug: IMM0306

First Posted Date: 2023-04-10

Last Posted Date: 2023-04-10

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 154

Registration Number: NCT05805943

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Advanced Cholangiocarcinoma
Advanced Lung Cancer
Advanced Gastric Carcinoma

Interventions: Drug: IMM2902

First Posted Date: 2023-04-10

Last Posted Date: 2023-04-10

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 105

Registration Number: NCT05805956

Locations: 🇨🇳
301 Hospital, Beijing, China
🇨🇳
Fudan University Cancer Hospital, Shanghai, China

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Breast Cancer
Advanced Solid Tumor
Small Cell Lung Cancer
Non-small Cell Lung Cancer
Squamous Cell Cancer of Head and Neck
Colorectal Cancer

Interventions: Drug: IMM2520

First Posted Date: 2023-03-22

Last Posted Date: 2023-06-07

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 48

Registration Number: NCT05780307

Locations: 🇨🇳
Affilated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Phase 1

Not yet recruiting

Conditions: B-cell Non-Hodgkin's Lymphoma

Interventions: Drug: IMM0306
Drug: Lenalidomide capsule

First Posted Date: 2023-03-16

Last Posted Date: 2023-05-24

Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Target Recruit Count: 102

Registration Number: NCT05771883

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy